134 related articles for article (PubMed ID: 6197660)
1. Acute changes in nigral substance P content induced by drugs acting on dopamine, muscarine and GABA receptors.
Koshiya K; Kato T
Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):223-7. PubMed ID: 6197660
[TBL] [Abstract][Full Text] [Related]
2. Postsynaptic integration of cholinergic and dopaminergic signals on medium-sized GABAergic projection neurons in the neostriatum.
Harsing LG; Zigmond MJ
Brain Res Bull; 1998 Apr; 45(6):607-13. PubMed ID: 9566505
[TBL] [Abstract][Full Text] [Related]
3. Progabide reverses the nigral substance P reduction induced by chronic impairment of dopaminergic transmission.
Zivkovic B; Oblin A; Bartholini G
Eur J Pharmacol; 1985 Jun; 112(2):253-5. PubMed ID: 2411575
[TBL] [Abstract][Full Text] [Related]
4. The effects of dopamine and dopamine agonists on the release of 3H-GABA and 3H-5HT from rat nigral slices.
Kelly E; Jenner P; Marsden CD
Biochem Pharmacol; 1985 Aug; 34(15):2655-62. PubMed ID: 3925957
[TBL] [Abstract][Full Text] [Related]
5. Inhibition by apomorphine of the potassium-evoked release of [3H]-gamma-aminobutyric acid from the rat substantia nigra in vitro.
Arbilla S; Kamal LA; Langer SZ
Br J Pharmacol; 1981 Oct; 74(2):389-97. PubMed ID: 7317688
[TBL] [Abstract][Full Text] [Related]
6. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
Merchant KM; Bush LG; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
[TBL] [Abstract][Full Text] [Related]
7. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist.
Hanson G; Alphs L; Pradhan S; Lovenberg W
Neuropharmacology; 1981 Jun; 20(6):541-8. PubMed ID: 6165922
[No Abstract] [Full Text] [Related]
8. Comparison of effects of drugs on dopamine metabolism in the substantia nigra and the corpus striatum of rat brain.
Westerink BH; Korf J
Eur J Pharmacol; 1976 Nov; 40(1):131-6. PubMed ID: 991922
[TBL] [Abstract][Full Text] [Related]
9. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
Cobb WS; Abercrombie ED
Neuroscience; 2003; 119(3):777-86. PubMed ID: 12809698
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems.
Hanson GR; Alphs L; Wolf W; Levine R; Lovenberg W
J Pharmacol Exp Ther; 1981 Aug; 218(2):568-74. PubMed ID: 6166743
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of chronic haloperidol and sulpiride treatment on nigral and striatal GABA content.
Nicoletti F; Patti F; Condorelli DF; Rampello L; Giammona G; Di Giorgio RM; Canonico PL; Scapagnini U
J Neurochem; 1981 Oct; 37(4):1048-51. PubMed ID: 7320718
[TBL] [Abstract][Full Text] [Related]
12. Increase of tyrosine hydroxylase and its mRNA in the rat substantia nigra pars reticulata by diazepam and picrotoxin.
Stork O; Hashimoto T; Obata K
Neurosci Res; 1994 Feb; 19(1):73-80. PubMed ID: 7911985
[TBL] [Abstract][Full Text] [Related]
13. Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.
Nicoletti F; Clementi G; Patti F; Canonico PL; Di Giorgio RM; Matera M; Pennisi G; Angelucci L; Scapagnini U
Brain Res; 1982 Nov; 250(2):381-5. PubMed ID: 6293644
[TBL] [Abstract][Full Text] [Related]
14. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
[TBL] [Abstract][Full Text] [Related]
15. Quantitative radioimmunocytochemical evidence that haloperidol and SCH 23390 induce opposite changes in substance P levels of rat substantia nigra.
Cruz CJ; Beckstead RM
Brain Res; 1988 Aug; 457(1):29-43. PubMed ID: 2458801
[TBL] [Abstract][Full Text] [Related]
16. The effects of elevating gamma-amino butyrate content in the substantia nigra on the behaviour of rats.
Matsui Y; Kamioka T
Eur J Pharmacol; 1978 Aug; 50(3):243-51. PubMed ID: 689078
[TBL] [Abstract][Full Text] [Related]
17. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
18. The effects of chronic haloperidol administration on GABA receptor binding.
Huffman RD; Ticku MK
Pharmacol Biochem Behav; 1983 Aug; 19(2):199-204. PubMed ID: 6314387
[TBL] [Abstract][Full Text] [Related]
19. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation.
Sonsalla PK; Gibb JW; Hanson GR
Eur J Pharmacol; 1984 Oct; 105(1-2):185-7. PubMed ID: 6208043
[TBL] [Abstract][Full Text] [Related]
20. Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons.
Di Chiara G; Porceddu ML; Morelli M; Mulas ML; Gessa GL
Naunyn Schmiedebergs Arch Pharmacol; 1979 Mar; 306(2):153-9. PubMed ID: 571967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
